| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Fluticasone furoate/ umeclidinium/ vilantero |
| Brand | Trelegy™ Ellipta™ |
| Indication | For the maintenance treatment of adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA. |
| Assessment Process | |
| Rapid review commissioned | 30/04/2018 |
| Rapid review completed | 18/06/2018 |
| Rapid review outcome | A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
The HSE has approved reimbursement; August 2018.
